Home » Trials » SLCTR/2022/004
Double-blind Randomized control trial of Ozone therapy for the treatment of chronic wounds
-
SLCTR Registration Number
SLCTR/2022/004
Date of Registration
The date of last modification
Mar 21, 2022
Scientific Title of Trial
Double-blind Randomized control trial of Ozone therapy for the treatment of chronic wounds
Public Title of Trial
Double- blind Randomized controlled trial comparing the efficacy of topical Ozone-Oxygen mixture therapy with sham procedure in the treatment of patients with chronic wounds..
Disease or Health Condition(s) Studied
Chronic wounds
Scientific Acronym
None
Public Acronym
None
Brief title
None
Universal Trial Number
U1111-1263-4683
Any other number(s) assigned to the trial and issuing authority
ERC/2020/71
What is the research question being addressed?
Is topical Ozone therapy effective in healing of chronic wounds compared to sham procedure?
Type of study
Interventional
Study design
Allocation
Randomized controlled trial
Masking
Double blinded : Participants, Healthcare providers
Control
Placebo
Assignment
Parallel
Purpose
Supportive care
Study Phase
Phase 3
Intervention(s) planned
The study setting includes the professorial surgical wards and surgical clinics of Teaching Hospital Anuradhapura. Participants will be patients aged 18 or over with chronic wounds, who have not received topical Ozone therapy previously.
Method of randomization includes a covariates adaptive randomization based on age and gender. The randomization will done via computer generated programme which takes in to account the above parameters.
Intervention: The EXT 120 Ozone Generator will be used to generate the ozone/oxygen mixture at differing concentrations as required. The wound will be cleaned initially with the ozonized water (produced by the EXT 120 Ozone generator). A bag will be placed over and around the chronic wound and the gas of Ozone/Oxygen mixture of differing concentrations generated by the Ozone generator will be used to fill the bag surrounding the chronic wound and continued for 30 minutes.
The ozone/oxygen mixture is initially applied at higher concentrations (96% oxygen and 4% (80 µg/ml) Ozone) three times a week until the wound size is reduced by 50% or a maximum of four weeks. Then the dose is decreased to a lower concentration (98% oxygen and 2% (40 µg/ml) Ozone) and applied twice a week for another 4 weeks. Finally, the ozone concentration will be reduced to 99% oxygen and 1% (20 µg/ml) Ozone and applied twice a week for another 4 weeks. The total period of intervention for a patient will be 12 weeks. Standard of care for chronic wounds consists of cleaning, dressing, and in some cases debridement of the wound. It further includes swabbing for identification of infection and use of antibiotics if indicated.
Control: The procedure for the control arm participants will be that the EXT 120 Ozone Generator is set to the inactive mode and room air delivered in the same manner. Treatment frequency will be the same. Control arm participants will also receive the standard wound care as usual.
Inclusion criteria
Males and females who are 18 years or older with chronic wounds (wounds that fail to proceed through the normal phases of wound healing in an orderly and timely manner).
Exclusion criteria
• Patients with known contraindication to ozone therapy • Any patient who had previously been treated with ozone or hyperbaric oxygen therapy, • A history of collagen disease, • Pregnant mothers. • Participants with cognitive impairment (patients with psychotic illnesses, learning disability).
Primary outcome(s)
1.
|
[ At baseline and at the end of weeks 1, 2, 3, 4, 6, 8, 10, and 12. ] |
Secondary outcome(s)
1.
|
[ At baseline and at the end of weeks 1, 2, 3, 4, 6, 8, 10, and 12. ] |
Target number/sample size
80 (40 in a group)
Countries of recruitment
Sri Lanka
Anticipated start date
2022-03-23
Anticipated end date
2023-03-23
Date of first enrollment
Date of study completion
Recruitment status
Pending
Funding source
Integrated Palliative Care Research Centre
Regulatory approvals
Status
Approved
Date of Approval
2021-04-23
Approval number
ERC/2020/71
Details of Ethics Review Committee
Name: | Faculty of Medicine and Allied Sciences, Rajarata University |
Institutional Address: | Faculty of Medicine and Allied Sciences, Rajarata University 50008 Anuradhapura-Saliyapura, Anuradhapura, Sr Lanka. |
Telephone: | +94 (0)25 2053633 |
Email: | ethicsreviewcommittee@gmail.com |
Contact person for Scientific Queries/Principal Investigator
Dr.Senaka Pilapitiya
Senior Lecturer
Faculty of Medicine and Allied science Rajarata University
0777281023
senaka.pilapitya@gmail.com
Contact Person for Public Queries
Dr. Sujeewa Priyantha Bandara Thalgaspitiya
Senior Lecturer
Department of Surgery
Faculty of Medicine and Allied Sciences Rajarata University
0778084465
sujeewathale@yahoo.com
Do the investigators plan to share identified individual clinical trial participant-level data (IPD)?
No
IPD sharing plan description
Study protocol available
No
Protocol version and date
Not Available
Protocol URL
Not Available
Results summary available
No
Date of posting results
Date of study completion
Final sample size
Date of first publication
Link to results
Brief summary of results